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Background/Aims: The objective of this study was to determine the efficacy 
and safety of add-on therapy with certolizumab pegol (CZP) in active rheu-
matoid arthritis (RA) patients of a single ethnicity. 
Methods: In this 24-week, phase 3, randomized, double-blind, placebo-con-
trolled trial, eligible patients (n = 127) were randomized 2:1 to subcutaneous 
CZP + methotrexate (MTX; 400 mg at week 0, 2, and 4 followed by 200 mg 
every 2 weeks) or placebo + MTX. 
Results: At week 24, the American College of Rheumatology criteria for 20% 
(ACR20) response rate was significantly greater with CZP + MTX than with 
placebo (66.7% vs. 27.5%, p < 0.001). Differences in ACR20 response rates for 
CZP vs. placebo were significant from week 1 (p < 0.05) and remained signif-
icant through week 24. The CZP group reported significant improvement in 
physical function and disability compared to the placebo group (p < 0.001) at 
week 24, as assessed by Korean Health Assessment Questionnaire-Disability 
Index (KHAQ-DI). Post hoc analysis indicated that the proportion of patients 
who had ACR70 responses, Disease Activity Score 28 (DAS28) low disease 
activity, and DAS28 remission at week 24 was greater in CZP + MTX-treated 
patients who achieved a decrease in DAS28 ≥ 1.2 (43.8%) at week 4 than in 
nonresponders. Among 18 (22.2%) and 14 patients (35.0%) in CZP and place-
bo groups who had latent tuberculosis (TB), none developed active TB. Most 
adverse events were mild or moderate.
Conclusions: CZP treatment combined with MTX in active RA patients with 
moderate to severe disease activity and an inadequate response to MTX 
resulted in rapid onset of efficacy, which is associated with better clinical 
outcome at week 24 and has an acceptable safety profile, especially in an in-
termediate TB-burden population. 
Keywords: Rheumatoid arthritis; Certolizumab; Methotrexate; Tumor ne-
crosis factor inhibitor; Clinical trial
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory 
disease associated with significant morbidity and mor-
tality. The treatment of RA has shown remarkable ad-
vancement since the development of tumor necrosis 
factor (TNF) inhibitors added an effective armament on 
the synthetic disease-modifying anti-rheumatic drugs 
(DMARDs), such as methotrexate (MTX) and hydroxy-
chloroquine [1]. In addition to the new targeted biolog-
ics, the refinement of TNF inhibiting agents has been 
underway, which includes a fully human anti-TNF anti-
body [2] and a PEGylated anti-TNF Fab antibody [3], cer-
tolizumab pegol (CZP). 
CZP has shown clinical efficacy in the treatment of 
RA with moderate to severe disease activity either as a 
monotherapy or in combination with MTX and other 
DMARDs [3-5]. The combination of CZP and MTX was 
superior in the prevention of radiographic progression 
and in the improvement of physical function compared 
with MTX monotherapy [3,4]. Improvements in clinical 
outcomes have been achieved from the earliest visit after 
beginning of therapy (typically week 1) [3,4]. 
Previous studies have shown that reducing clinical 
disease activity as much as possible may result in the 
maximal reduction of disability [6-8]. In addition, ear-
lier response to treatment is predictive of the long-term 
outcome [6]. Disease activity at week 12 of treatment with 
TNF inhibitors has been related to long-term clinical 
and radiographic outcomes [9]. Furthermore, rapid at-
tainment of clinical response at week 6 was associated 
with faster, more sustained improvements in patient-
derived outcomes and with a better chance of achieving 
remission at week 52 compared to response at week 12 
[10]. 
This study was a phase 3, 24-week, randomized, dou-
ble-blind, placebo-controlled trial in which patients 
with moderate to severe RA and inadequate response 
to MTX could be enrolled. The purpose of this study 
was to determine the efficacy and safety of CZP in RA 
patients from a single ethnicity. In addition, this study 
analyzed whether early response to treatment is associ-
ated with better 24-week clinical outcome.
METHODS
Study setting and design
This was a 24-week, phase 3, double-blind, randomized, 
multicenter, placebo-controlled study conducted from 
December 2009 through August 2011 at 15 centers in 
Korea (NCT00993317). The Institutional Review Board 
(KNUH_09-0078) at each participating center approved 
the study protocol. All patients provided written in-
formed consent, and the study was conducted in accor-
dance with the principles of the Declaration of Helsinki 
as well as the relevant regulations and guidelines [11]. 
Eligible patients were randomized 2:1 to receive either 
CZP 200 mg subcutaneously every 2 weeks following a 
loading dose of CZP 400 mg at week 0, 2 and 4, or place-
bo (0.9% saline), plus MTX. All patients continued MTX 
treatment at the same dose and route of administration 
as at entry. Patients who failed to achieve a response ac-
cording to the American College of Rheumatology crite-
ria for 20% (ACR20) improvement at week 12 (and con-
firmed at the week 14 visit) were considered treatment 
failures. After the week 14 dosing, these patients and pa-
tients who completed the study at week 24 were offered 
the choice of entering the open-label extension (OLE) 
study. If the patients elected to enter the OLE study, they 
were to complete the assessments at week 24/withdrawal 
assessments at week 16 of the present study.
Participants
Eligible patients were aged 18 to 75 years with a diag-
nosis of RA, as defined by ACR 1987 criteria [12], for at 
least 6 months duration but not longer than 15 years. 
Patients had to have active disease at screening and at 
baseline, defined by ≥ 9 tender joint count based on 68 
joints, ≥ 9 swollen joint count based on 66 joints and 
either erythrocyte sedimentation rate (ESR) ≥ 30 mm/hr 
(Westergren) or C-reactive protein (CRP) ≥ 15 mg/L [13]. 
MTX had to be stable for at least 8 weeks prior to base-
line visit with a minimum dose of 10 mg weekly. 
Exclusion criteria included any active infection (in-
cluding currently active tuberculosis [TB]), positivity 
for hepatitis B virus surface antigen (HBsAg), hepatitis 
C antibody (HCV Ab), or human immunodeficiency vi-
rus (HIV) serum testing, uncontrolled medical diseas-
es, and rheumatic diseases other than RA. Patients were 
also excluded if they had received any biological therapy 
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for RA within 24 weeks prior to baseline (12 weeks for 
etanercept), had a severe hypersensitivity or anaphylac-
tic reaction with a biological agent, or had been resistant 
to previous anti-TNF therapy. Oral corticosteroids had 
to be stable for at least 4 weeks and during the trial with 
maximum dose of 10 mg/day prednisolone equivalent. 
Doses of nonsteroidal anti-inflammatory drugs were 
fixed for 2 weeks prior to baseline visit and during the 
trial. 
Patients were screened for TB according to the guide-
lines using skin test with purified protein derivatives 
(PPD) and chest X-ray. If the PPD skin test was positive 
(induration ≥ 5 mm) or the patient had had close contact 
with patients with active TB, but there was no clinical 
or radiologic evidence of TB, patients could be enrolled 
into the trial after adequate treatment for latent TB with 
isoniazid (up to 300 mg) initiated at least 1 month before 
randomization.
Efficacy assessments
Efficacy assessments were carried out at baseline and 
at week 1, 2, 4, 6, 8, 12, 14, 20, and 24/withdrawal. The 
primary efficacy endpoint was the ACR20 response at 
week 24. The secondary efficacy variables were ACR20 
response at week 12, ACR50/ACR70 response at week 12 
and 24, and Korean Health Assessment Questionnaire-
Disability Index (KHAQ-DI) at week 24 [14,15]. Other ef-
ficacy variables included ACR20/ACR50/ACR70 response 
rates at other time points, ACR core components, health-
related quality of life (HRQoL) as measured by the Short 
Form-36 (SF-36) health assessment tool [16], Disease Ac-
tivity Score in 28 joints calculated by using ESR (DAS28 
[ESR]), European League Against Rheumatism (EULAR) 
response criteria, and ESR [17].
Among the secondary efficacy endpoints, patient-re-
ported outcomes (PRO) included pain, patient’s global 
assessment of disease activity, physical function assess-
ment using the KHAQ-DI, and HRQoL assessed using 
the SF-36 Health Survey. 
Safety evaluations
Safety was assessed based on reported adverse events 
(AEs) which were assessed at all visits and at 12-week 
follow-up after the last dose of investigational product. 
Physical examination, laboratory tests, and chest radiog-
raphy were monitored at predefined schedule. AEs that 
required hospitalization, resulted in death, or caused 
disability were defined as serious AEs (SAEs). For immu-
nologic analyses, auto-antibodies such as anti-double 
stranded DNA and antinuclear antibodies were mea-
sured at baseline and week 24/withdrawal visit and anti-
CZP antibodies at baseline, week 1, 2, 4, 6, 8, 12, and 24.
Statistical methods
The sample size was determined using predicted rate 
of ACR20 response with 2:1 randomization ratio for 
CZP and placebo groups on the assumption of ACR20 
response of 50% in the CZP group and 21% in the pla-
cebo group. A sample size of 80 and 40 patients in CZP 
and placebo groups respectively was estimated to be re-
quired to provide 90% power for a two-tailed test with 
an alpha of 0.05.
Efficacy analyses were performed using the full anal-
ysis set (FAS) population (n = 121). For the responder 
analyses, patients who withdrew for any reason or used 
rescue medication were considered as nonresponders 
from that time point onwards (nonresponder imputa-
tion). Sensitivity tests were carried out on the data im-
puted using the last observation carried forward (LOCF) 
method. All secondary and other endpoints, apart from 
responder analyses, were imputed using LOCF. Where 
analysis of covariance was carried out on an efficacy 
endpoint, baseline value was included in the model as a 
covariate and treatment group as a factor. Comparisons 
between the CZP + MTX and placebo + MTX groups 
were performed using logistic regression with treat-
ment group as a factor. Odds ratios and 95% confidence 
intervals are presented. p values of < 0.05 were consid-
ered to be statistically significant. 
Safety and tolerability analyses were performed in the 
safety population in all randomized patients who re-
ceived at least 1 dose of study drug. The number and 
percentages of patients reporting AEs were tabulated 
and analyzed per the Medical Dictionary for Regulatory 
Activities coding terms.
RESULTS
A total of 127 patients were randomized into the study. 
Of these, 121 patients (FAS) received either CZP (n = 81) 
or placebo (n = 40) plus MTX (Fig. 1). Substantially fewer 
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patients were withdrawn due to lack of efficacy or AEs 
related to worsening of RA disease in the CZP + MTX 
group compared to placebo + MTX group (45% vs. 21%). 
At week 24, 58 patients (71.6%) in the CZP group complet-
ed the study compared with 20 patients (50.0%) in the 
placebo group. The mean age, percentage of female, body 
mass index, mean duration of RA, and rheumatoid factor 
positivity were similar between the groups (Table 1). 
At week 24, the ACR20 response rate (primary end-
point) was significantly greater in the CZP + MTX 
group compared to the placebo + MTX group (66.7% vs. 
27.5%, p < 0.001) (Fig. 2A). ACR20 response rate at week 
12 was also statistically significant for the CZP + MTX 
group compared to the placebo + MTX group (64.2% 
vs. 37.5%, respectively; p = 0.006). Meaningful differenc-
es in ACR20 response rates between treatment groups 
began at week 1 (p = 0.013) and remained through week 
24 (p < 0.05 for each comparison). The slope of increase 
Figure 1. Disposition of patients. FAS, full analysis set; 
MTX, methotrexate; CZP, certolizumab pegol. aCZP 200 mg 
every 2 weeks is preceded by CZP 400 mg at weeks 0, 2, and 4.
176 Screened for eligibility
127 Randomized
40 Placebo + MTX 81 CZP 200 mg + MTXa
20 (50%) Completed week 24
20 (50.0%) Withdrawn overall
2 (5.0%) Adverse events
18 (45.0%) Lack of efficacy
58 (71.6%) Completed week 24
23 (28.4%) Withdrawn overall
4 (4.9%) Adverse events
17 (21.0%) Lack of efficacy
2 (2.4%) Other reason
18 (45.0%) Withdrawn due to 
lack of efficacy at week 16
17 (21.0%) Withdrawn due to 
lack of efficacy at week 16
49 (27.8%) 
Screen failures
6 Excluded from 
the FAS
Table 1. Baseline characteristics of the FAS population 
Characteristic Placebo + MTX (n = 40) CZP 200 mg + MTX (n = 81)
Age, yr 50.8 ± 11.1 51.6 ± 11.7
Female sex 35 (87.5) 72 (88.9)
BMI, kg/m2 22.8 ± 3.4 23.0 ± 3.1
Disease duration, yr 5.5 ± 4.6 6.5 ± 4.2
Tender joint count 25.68 ± 14.69 25.06 ± 14.39
Swollen joint count 17.70 ± 11.32 16.07 ± 9.04
KHAQ Disability Index 1.54 ± 0.74 1.42 ± 0.68
Patient’s assessment of arthritis pain, 0–100 VAS 68.10 ± 21.57 62.23 ± 19.20
Patient’s global assessment, 0–100 VAS 66.83 ± 21.26 58.69 ± 21.00
Physician’s global assessment, 0–100 VAS 63.18 ± 17.42 65.20 ± 15.69
DAS28 using the ESR 7.46 ± 1.29 7.33 ± 1.09
ESR, mm/hr 40.00 (15.0–117.0) 50.00 (0.0–120.0)
CRP, mg/L 18.81 (0.6–142.6) 11.89 (0.4–123.1)
RF positive 32 (80) 64 (79)
Treatment status
MTX dose, mg/wk 13.5 ± 2.9 13.4 ± 2.5
Steroid use 35 (87.5) 70 (86.4)
PPD skin test positivity 14 (35.0) 18 (22.0)
Values are presented as mean ± SD, number (%), or median (range). PPD skin test positivity was defined as induration ≥ 5 mm 
in diameter.
FAS, full analysis set; MTX, methotrexate; CZP, certolizumab pegol; BMI, body mass index; KHAQ, Korean Health Assessment 
Questionnaire; VAS, visual analog scale; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; CRP, C-reac-
tive protein; RF, rheumatoid factor; PPD, purified protein derivative.
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in ACR20 response rate between time points was most 
steep at week 1, followed by week 2 and week 4 which 
were then followed by sustained but slower improve-
ments. The ACR50 and ACR70 responses at week 24 
were statistically significant when comparing the CZP 
+ MTX group with the placebo + MTX group (43.2% vs. 
20.0%, p = 0.014 and 17.3% vs. 2.5%, p = 0.047, respective-
ly) (Fig. 2A). One patient in the placebo + MTX group 
and 14 patients in the CZP + MTX group achieved an 
ACR70 response at week 24 (Fig. 2B). A treatment differ-
ence in improvement in DAS28 was observed by week 1 
for patients receiving CZP + MTX compared to placebo 
+ MTX (mean change from baseline: –0.70 vs. –0.22, re-
spectively; p < 0.001), and was maintained until week 24 
(–2.03 vs. –0.94, p < 0.001) (Fig. 2C). For the CZP + MTX 
group, by week 4, the mean change of DAS28 from base-
line approached half of the improvement seen at week 
24. EULAR good/moderate response rates at weeks 4 and 
24 for CZP + MTX group were 56.5% and 81.3%, respec-
tively; versus 15.4% and 48.7%, respectively, for placebo + 
MTX group (Fig. 2D). 
We next questioned whether responses at as early as 
week 4 would influence week 24 outcomes. At week 4, 
both ACR20 and EULAR good/moderate response rates 
were higher than 50% and the mean change of DAS28 
from baseline was approximated as almost half of the 
Figure 2. Clinical efficacy of certolizumab pegol (CZP) + methotrexate (MTX) or placebo (PBO) + MTX in the treatment of 
patients with active rheumatoid arthritis for 24 weeks. (A) American College of Rheumatology (ACR) 20%, 50%, and 70% re-
sponse criteria (ACR20, ACR50, and ACR70) response rates at week 24. (B) ACR20, ACR50, and ACR70 response rates over time, 
nonresponder imputation (NRI). (C) Mean changes from baseline in the Disease Activity Score in 28 joints (DAS28; erythrocyte 
sedimentation rate [ESR]). (D) European League Against Rheumatism (EULAR) response criteria good/moderate response 
rates over time, NRI. ap ≤ 0.05, bp ≤ 0.001 (vs. PBO + MTX, NRI), and cp ≤ 0.05, dp ≤ 0.001 (vs. PBO + MTX at each time point, last 
observation carried forward).
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improvement seen at week 24 for CZP + MTX group. 
Responders were then defined as patients achieving a 
decrease in DAS28 (ESR) of ≥ 1.2 from baseline. Post hoc 
analysis revealed that the proportion of patients who 
had ACR70 responses, DAS28 low disease activity (LDA; 
defined as a DAS28 ≤ 3.2), and DAS28 remission (defined 
as a DAS28 ≤ 2.6) at week 24 was greater in the popula-
tion of week 4 responders than in nonresponders (Fig. 3). 
CZP + MTX-treated patients who achieved a DAS28 ≥ 1.2 
(43.8%) at week 4 had similar demographics and disease 
characteristics at baseline (data not shown) compared 
with nonresponders. 
In addition to clinical outcomes, CZP + MTX pro-
vided measurable improvements in PROs, including 
pain, patient’s global assessment for disease activity, 
KHAQ-DI, and HRQoL over placebo + MTX. At week 
1, CZP + MTX group reported significant improvement 
in pain, patient’s global assessment, and KHAQ-DI. The 
mean change from baseline in KHAQ-DI at week 24 was 
–0.54 with CZP + MTX compared to –0.17 with placebo 
+ MTX (p < 0.001) (Fig. 4). Patients in the CZP + MTX 
group showed greater improvements from baseline in 
HRQoL as assessed by Physical Component Summary 
score (PCS) and Mental Component Summary score 
(MCS) of SF-36 compared with those in the placebo + 
MTX group. The differences between treatment groups 
were small for the PCS compared to the MCS, although 
all SF-36 domain sub-scores were numerically improved 
in patients treated with CZP + MTX compared to pla-
cebo + MTX. In a post hoc analysis, DAS28 response at 
week 4 was associated with clinically significant im-
provements in PROs such as pain and patient’s global 
assessment at week 24. 
Of the 127 patients in the safety set (patients who re-
ceived at least one injection of study drug), a total of 164 
treatment emergent adverse events (TEAEs) were re-
ported in 56 patients (65.9%) treated with CZP + MTX, 
whereas 60 TEAEs were reported in 24 patients (57.1%) 
treated with placebo + MTX (Table 2). The majority of 
AEs in both treatment groups were mild to moderate 
in nature. The most frequently reported adverse events 
were infections, followed by gastrointestinal disorders 
and injection site reactions. Infectious AEs were report-
ed at similar rates in the CZP + MTX group (34.1%) and 
the placebo + MTX group (28.6%). The most frequent 
infectious AEs were upper respiratory tract infections 
and urinary tract infections. AEs leading to withdrawal 
from the study were reported in CZP + MTX patients 
(n = 4, 4.7%) and placebo + MTX patients (n = 2, 4.8%). A 
total of 15 SAEs were experienced by eight patients (9.4%) 
in the CZP + MTX group compared to none in the pla-
cebo + MTX group. The most common SAEs were infec-
tions occurring in six CZP-treated patients. At baseline, 
18 (22.2%) and 14 patients (35.0%) in the CZP + MTX and 
Figure 3. Proportion of American College of Rheumatology 
(ACR) 70 responders, patients with low disease activity (LDA), 
and patients in Disease Activity Score in 28 joints (DAS28) 
remission at week 24 in patients who achieved a ≥ 1.2-point 
reduction compared with patients who achieved a < 1.2-re-
duction in DAS28 at week 4.
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placebo + MTX groups, respectively, had PPD indura-
tions ≥ 5 mm in diameter (Table 1). All of these patients 
except for one received prophylactic treatment for TB. 
One subject in the placebo + MTX group did not receive 
TB prophylaxis despite PPD positivity and was reported 
as a protocol deviation. This subject didn’t experience 
TB during the study. Two patients developed TB after 
147 and 167 days of exposure to CZP. Both patients were 
PPD negative at baseline. 
There were no cases of death, demyelinating diseas-
es, malignancy, or lupus-like syndrome. The incidence 
of conversion of antinuclear antibody from negative at 
baseline to positive at week 24 was higher in the CZP 
+ MTX group (11.1%) than the placebo + MTX group 
(7.1%). One patient (2.4%) in the placebo group converted 
anti-double stranded DNA (anti-dsDNA) antibody from 
negative at baseline to positive at week 24. Anti-CZP an-
tibodies were detected in 1.3% and 3.8% of CZP + MTX 
group at week 12 and week 24, respectively.
DISCUSSION
This 24-week randomized controlled trial demonstrated 
that addition of CZP (400 mg at week 0, 2, and 4, fol-
lowed by 200 mg every other week) to MTX in active 
RA patients who had a previous inadequate response 
to MTX alone rapidly improved disease activity. This 
study was performed in patients of single ethnicity with 
an intermediate TB burden, and demonstrated a similar 
efficacy of CZP treatment compared with that of previ-
ous studies on a multi-ethnicity background [3,4], and 
comparable risks for AEs including TB infection.
The primary endpoint, ACR20 response rate at week 
24, was 66.7% in the CZP + MTX group, which was slight-
ly higher compared to 58.5% and 57.3% in Rheumatoid 
Arthritis Prevention of structural Damage 1 (RAPD1) [3] 
and RAPID2 [4] trials, respectively, but the response rate 
of placebo group was also higher in this study. The odds 
of being an ACR20 responder at week 24 was 5.3 times 
greater for patients in the CZP 200 mg plus MTX group 
compared to the placebo + MTX group (95% confidence 
interval, 2.3 to 12.1; p < 0.001). The efficacy of CZP + MTX 
was also demonstrated for all secondary and other end-
points, showing rapid response as early as week 1 and 
consistent improvement throughout week 24 compared 
to placebo + MTX. A rapid change in ACR20 response 
rate, DAS28 reduction and KHAQ-DI improvement 
continued until week 4, which was followed by slower 
but continuous improvements at subsequent visits. 
At week 24, a higher percentage of patients in the CZP 
+ MTX group achieved ACR50 and ACR70 response 
compared to those in the placebo + MTX group. CZP + 
MTX treated patients reported significant improvement 
in physical function and disability compared to placebo 
+ MTX patients (p < 0.001), as assessed by the KHAQ-DI. 
Table 2. Summary of AEs
AE
Placebo + MTX (n = 42) CZP + MTX (n = 85)
No. of patient (%)a Total event No. of patient (%)a Total event
Total AEs 24 (57.1) 60 56 (65.9) 164
Infectious AEs 12 (28.6) 12 29 (34.1) 46
Upper respiratory tract infection 5 (11.9) 5 12 (14.1) 12
Urinary tract infections 1 (2.4) 1 2 (2.4) 2
Tuberculosis 0 0 2 (2.4) 2
Neoplasms 0 0 2 (2.4) 2
Serious AEs 0 0 8 (9.4) 15
Serious infections 0 0 6 (7.1) 8
Nervous system disorders 0 0 2 (2.4) 4
AEs leading to withdrawal 2 (4.8) 6 4 (4.7) 8
AEs leading to death 0 0 0 0
AE, adverse event; MTX, methotrexate; CZP, certolizumab pegol. 
aPatients who experienced more than one AE in a category are listed once.
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Furthermore, CZP-treated patients showed an improve-
ment from baseline in health-related quality of life, as 
assessed by SF-36 PCS and MCS.
In a post hoc analysis, patients that had decreased 
DAS28 ≥ 1.2 from baseline response at week 4 to CZP + 
MTX showed a better response in clinical outcomes and 
PROs at week 24, revealing that early clinical response to 
CZP treatment is associated with good clinical respons-
es in terms of ACR70, LDA, and DAS28 remission after 
longer term treatment at week 24. Although it was not 
the focus of the present trial, it was of interest that the 
earlier responders at week 4 had a better clinical out-
come measure. Previous studies showed that the level of 
disease activity at 3 months was related to the increased 
possibility of LDA or remission after 1 year of treatment 
with TNF inhibitors [6]. Furthermore, patients with an 
earlier clinical response to CZP + MTX at week 6 were 
more likely to have a better long-term clinical response 
at week 52 [10]. The response to anti-TNF treatment at 
week 6 may predict drug discontinuation at 3 months 
[18]. These results including the present study impli-
cate that the faster response to TNF blockade predicts 
improved long-term clinical outcome, which may help 
reduce unnecessary drug exposure by earlier determina-
tion of alternative therapy [10]. 
CZP + MTX in the present trial had a comparable 
safety profile to other anti-TNFs, with a low incidence of 
discontinuations due to AEs [3,4,19-21]. The percentage 
of CZP patients reporting infectious AEs was similar to 
those reported for other TNF inhibitors in a population 
of the same ethnicity [22] and in heterogeneous popula-
tions of multi-ethnicity [3-5]. There were no deaths or 
malignancy among patients who participated in this 
study. 
The incidence of serious infections, including TB, 
in the CZP + MTX group was consistent with those 
reported with anti-TNF treatments [23,24]. In the pres-
ent study which was performed in an intermediate 
TB-burden population (92/100,000 general population) 
[25], TB occurred in two patients with CZP treatment. 
Although patients who were considered to have a risk 
of TB were treated with a prophylactic regimen based 
on the current clinical procedures using guidelines for 
latent TB treatment during TNF antagonist use [26,27] 
TB may still occur in patients with negative PPD skin 
tests, representing new infections rather than reactiva-
tions [28]. The comparable incidence of TB in this study 
with the trials of TNF inhibitors performed in mixed 
TB-burden populations indicates the safety of CZP ther-
apy in patients living in countries with an intermediate 
prevalence of TB, if appropriate prophylactic measures 
are applied [4,19-21]. Thus, CZP + MTX has an accept-
able safety profile for the treatment of patients with RA 
which was in line with other reports of CZP [3,29] and 
with reports of other anti-TNFs in the same population 
[22].
Limitations of this study include the short duration of 
24 weeks, small size of study population and lack of ra-
diographic outcome measures. Further long-term data 
by the OLE to this study and additional registry pro-
grams may assist in identification of better predictors of 
long-term clinical outcome.
In conclusion, combined treatment with CZP in pa-
tients with active RA and an inadequate response to 
MTX resulted in rapid onset of efficacy which is asso-
ciated with better clinical outcome at week 24 and has 
an acceptable safety profile, even in an intermediate 
TB-burden population with adequate TB prophylaxis 
management. Together with established efficacy, these 
results augment the available evidence that CZP treat-
ment is safe and effective in the treatment of RA patients 
with moderate to severe disease activity.
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KEY MESSAGE 
1. Certolizumab pegol treatment combined with 
methotrexate (MTX) in patients with active 
rheumatoid arthritis and an inadequate re-
sponse to MTX resulted in rapid onset of effica-
cy.
2. Rapid onset of efficacy was associated with bet-
ter clinical outcome at week 24, even in an inter-
mediate tuberculosis (TB)-burden population 
with adequate TB prophylaxis management.
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